# PT-141 FAQ: Common Questions About Bremelanotide, Answered > PT-141 FAQ: what it is, what it's used for, how it works, the approved dosage, side effects, blood pressure, and hyperpigmentation — direct, cited answers about bremelanotide. Direct answers to the questions readers actually ask, each cited to the trial and label record where it makes a quantitative claim. ## What is PT-141? PT-141 is the research designation for bremelanotide, a synthetic cyclic heptapeptide analogue of alpha-MSH that activates central melanocortin MC3R/MC4R receptors [1]. It works in the brain to influence sexual desire and arousal, and it is FDA-approved for one indication — HSDD in premenopausal women [6]. ## What is PT-141 peptide? The PT-141 peptide is a cyclic seven-amino-acid lactam peptide, sequence Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-OH [1]. It is structurally related to melanotan II but carries a carboxylic-acid C-terminus instead of an amide, with a molecular weight of 1025.2 Da [6]. ## What does the PT-141 peptide do? It activates melanocortin receptors in the brain to influence sexual desire and arousal centrally [1]. Unlike PDE-5 inhibitors, which act on blood flow, PT-141 works on the neural circuitry of sexual motivation — a fundamentally different mechanism [1]. ## What is PT-141 used for? Its one FDA-approved use is acquired, generalized HSDD (distressing low sexual desire) in premenopausal women [6]. Uses in men, for erectile dysfunction, or in postmenopausal women are off-label and investigational, supported only by early-phase evidence [1]. ## Is PT-141 the same as bremelanotide? Yes. "Bremelanotide" is the international nonproprietary name (INN) for the molecule, and "PT-141" is its research and development designation [1]. The two names refer to one identical compound. ## What is bremelanotide? Bremelanotide is the FDA-approved melanocortin receptor agonist (NDA 210557, June 2019) indicated as a 1.75 mg subcutaneous as-needed injection for premenopausal women with HSDD [6]. PT-141 is the same molecule under its research name [1]. ## How does PT-141 work? By stimulating MC4R (and MC3R) in hypothalamic circuits such as the medial preoptic area, it is thought to engage dopamine pathways governing sexual desire, working centrally rather than peripherally [1]. A 2022 fMRI study confirmed it alters how the brain processes sexual cues [5]. ## What receptors does PT-141 act on? Chiefly the melanocortin 4 receptor (MC4R), with secondary MC3R agonism [1]. Both are central-nervous-system melanocortin receptor subtypes; activation of the peripheral MC1R accounts for the hyperpigmentation seen with frequent dosing [6]. ## Does PT-141 work through the brain or through blood flow? Through the brain. Unlike PDE-5 inhibitors, which act peripherally on vascular smooth muscle, PT-141 works centrally on the neural circuitry of sexual motivation [1]. It does not act on blood flow the way erectile blood-flow drugs do. ## What is a melanocortin receptor agonist? A molecule that activates one or more of the five melanocortin G-protein-coupled receptors (MC1R-MC5R) [1]. PT-141 targets the central MC3R/MC4R subtypes, the ones involved in sexual desire, rather than the full melanocortin family. ## Does PT-141 increase testosterone? No. PT-141 does not act via the HPG axis and does not directly raise testosterone [6]. Its effect on sexual desire is mediated by central melanocortin signaling in the brain, a separate pathway from the hormonal one. ## How is PT-141 different from PDE-5 inhibitors? PDE-5 inhibitors improve erectile blood flow peripherally, on vascular smooth muscle; PT-141 acts centrally on the melanocortin circuits governing desire and arousal [1]. They are fundamentally different mechanisms aimed at different parts of the response. ## What is the PT-141 dosage? The approved label dose is 1.75 mg subcutaneously as needed, with a maximum of one dose per 24 hours and eight per month [6]. This is reported here only as a label finding, not as a recommendation to self-administer. ## How much PT-141 should I take? This site reports doses only as research and label findings — for example, 1.75 mg subcutaneously as-needed in the RECONNECT trials — and gives no individual dosing recommendation [3]. PT-141 sold as a research chemical is for laboratory use only [6]. ## How much PT-141 to inject? The Phase 3 trials and the label used 1.75 mg subcutaneous as-needed, while Phase 2 dose-finding evaluated 0.75, 1.25, and 1.75 mg [6]. These are stated as findings from the record, not as a protocol for anyone to follow. ## What is the PT-141 dosage for women? For the approved HSDD indication in premenopausal women, the label specifies 1.75 mg subcutaneous as-needed at least 45 minutes before anticipated activity, no more than one dose per 24 hours and eight per month [6]. The 52-week extension confirmed the as-needed pattern [4]. ## How often can you take PT-141? The US label specifies the 1.75 mg subcutaneous dose as needed, with hard caps of no more than one dose per 24 hours and no more than eight doses per month [6]. Reported here as a label finding, not as a protocol. ## What are the side effects of PT-141? In the 52-week extension the most common drug-related events were nausea (40.4%), flushing (20.6%), and headache (12.0%) [4]. The label also notes injection-site reactions, nasal congestion, a transient blood-pressure increase, and focal hyperpigmentation with repeated dosing [6]. ## Why does PT-141 cause nausea? Nausea is the most common adverse event (~40% over long-term use) and the leading reason participants discontinued [4]. It is linked to central melanocortin (MC4R) signaling and is studied as a tolerability and injection-timing consideration [3]. ## Does PT-141 raise blood pressure? Yes, transiently. Ambulatory monitoring documented a transient rise in blood pressure with a small drop in heart rate after dosing [7]. The label contraindicates use in uncontrolled hypertension or known cardiovascular disease [6]. ## Does PT-141 cause skin darkening or hyperpigmentation? Focal hyperpigmentation of the face, gums, and breasts is reported with repeated frequent dosing and is attributed to MC1R activation [6]. It is more associated with high-frequency use than with the approved as-needed regimen. ## Is PT-141 safe? In trials no new safety signals emerged over 52 weeks, but the profile is real: common nausea, flushing, and headache, a transient blood-pressure increase, and a cardiovascular contraindication [4][6][7]. Material sold as a research chemical sits outside that medical oversight [6]. --- A plain research desktop reading the bremelanotide record straight — the one approved use, the honest tolerability profile, and the off-label evidence kept in its own window; no clinic behind the screen and nothing here dispensed, sourced, or sold.